• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Telo Genomics Corp (OP: TDSGF )

    0.0863 UNCHANGED
    Streaming Delayed Price Updated: 2:04 PM EST, Nov 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Telo Genomics Corp

    EXCLUSIVE: Telo Genomics' Smoldering Multiple Myeloma Prognostic Test Predicts Risk Of Disease Progression, Study Shows
    American Journal of Hematology accepts Telo Genomics' study on TeloViewSMM, a prognostic test for smoldering multiple myeloma. The test showed 85% positive and 73% negative predictive values, offering... 
    Via Benzinga
    Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
    EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation
    Toronto, Ontario--(Newsfile Corp. - October 26, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce... 
    Via Newsfile
    Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
    From FN Media Group LLC
    Via GlobeNewswire
    Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
    EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM – An Important Commercial Milestone Achieved
    TeloView Analyses Telomeres to Accurately Predict and Characterize Multiple Myeloma Toronto, ON – October 17, 2023 – Telo Genomics Corp. (OTCQB: TDSGF) (TSXV: TELO) (the “Company” or “Telo”) today... 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
    Toronto, ON – October 12, 2023 – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “TELO”) is pleased to announce that it has participated in the International Myeloma Society (“IMS”)... 
    Via FinancialNewsMedia
    Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study
    Toronto, Ontario--(Newsfile Corp. - September 14, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is... 
    Via Newsfile
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.